We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
President Trump vowed during his acceptance speech at the Republican National Convention that a coronavirus vaccine will be ready by the end of the year even as many experts continue to express skepticism about such an expedited timeline. Read More
Ology Bioservices, an Alachua, Fla.-based biologics contract development and manufacturing organization (CDMO), has been granted a contract worth up to $106.3 million from the U.S. Army to help out with COVID-19 vaccine and therapeutic production. Read More
The European Commission is ramping up its efforts to obtain COVID-19 vaccines for EU member states. The commission and AstraZeneca (AZ) signed a contract yesterday for the drugmaker to supply up to 400 million COVID-19 vaccine doses for the EU. Read More
Partner Therapeutics has enrolled the first patient in a phase 2 trial evaluating its inhaled Leukine (sargramostim) for hospitalized COVID-19 patients. Read More
Three ranking Democrats have asked a Virginia-based consulting firm to reveal details of its government contract for Operation Warp Speed’s chief adviser Moncef Slaoui, citing concerns that the contract allows the former pharma executive to skirt ethics rules and avoid disclosing potential conflicts of interest. Read More
Moderna’s coronavirus vaccine candidate was well-tolerated and worked well in elderly COVID-19 patients in a small, early-stage trial, the company said Wednesday, following promising results announced in July for younger patients. Read More
VBI received a $42 million contract from the Canadian government earlier this month to support its COVID-19 vaccine development program through phase 2 testing. Read More
The National Institutes of Health (NIH) said it plans to study an investigational antiviral from Gilead Sciences that proponents believe may offer significant advantages over remdesivir as a possible COVID-19 treatment. Read More
AstraZeneca has dosed the first participants in a phase 1 trial of its investigational monoclonal antibody product AZD7442 for preventing and treating COVID-19. Read More